<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956189</url>
  </required_header>
  <id_info>
    <org_study_id>200812110M</org_study_id>
    <nct_id>NCT00956189</nct_id>
  </id_info>
  <brief_title>Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome</brief_title>
  <official_title>Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yu-Li Veterans Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yu-Li Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators developed an easy identification model to identify metabolic syndrome in&#xD;
      patients with schizophrenia or schizoaffective disorder who received treatment of clozapine,&#xD;
      olanzapine, or risperidone. The accuracy of the investigators' models showed well. In the&#xD;
      study, the investigators aim to (1) to examine whether the developed identification models&#xD;
      can be generalized to patients taking other antipsychotics or patients with other diagnoses;&#xD;
      (2) to develop an easy risk score and validate it; (3) to switch antipsychotics to&#xD;
      amisulpride or aripiprazole for those with metabolic syndrome, and compare the changes of&#xD;
      metabolic parameters including adiponectin, and analyze their association with genetic&#xD;
      variants, demography, and clinical variables; (4) to establish models using artificial neural&#xD;
      network and statistic method to predict metabolic response after a switch to amisulpride or&#xD;
      aripiprazole; (5) to investigate the effect of antipsychotics on adiponectin gene expression&#xD;
      and secretion during the differentiation process of 3T3L1 adipocytes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic profile</measure>
    <time_frame>half/one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>half/one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amisulpride</intervention_name>
    <description>Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.</description>
    <arm_group_label>Amisulpride</arm_group_label>
    <other_name>Solian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <description>Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Stage I for identification of metabolic syndrome:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, mood&#xD;
             disorders, or anxiety disorders based on DSM-IV-TR criteria.&#xD;
&#xD;
          -  Age at least 20 years old.&#xD;
&#xD;
          -  The current antipsychotic drugs have been used for at least 3 months before&#xD;
             evaluation.&#xD;
&#xD;
          -  Psychiatrically stable with Clinical Global Impression of Severity scale (CGI-S) not&#xD;
             greater than 5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe uncontrolled medical illnesses, including cardiovascular, hepatic, renal and&#xD;
             metabolic diseases (eg. cancer, poor-control hypertension, diabetes mellitus, and&#xD;
             other metabolic diseases).&#xD;
&#xD;
          -  Organic mental or neurological disorder, substance abuse or dependence (alcohol,&#xD;
             amphetamine, heroin).&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Patients from Yuli Veterans Hospital, who attended our previous study of&#xD;
             identification model.&#xD;
&#xD;
        Stage II for switch response:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  The same as Stage I criteria.&#xD;
&#xD;
          -  Fulfill the metabolic syndrome criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The same as Stage I criteria except the 4th item.&#xD;
&#xD;
          -  Treated with depot form of antipsychotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chao-Cheng Lin, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yu-Li Hospital</name>
      <address>
        <city>Yu-Li</city>
        <state>Hualien County</state>
        <zip>981</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yu-Li Veterans Hospital</name>
      <address>
        <city>Yu-Li</city>
        <state>Hualien County</state>
        <zip>981</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Identification</keyword>
  <keyword>Prediction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

